BioNTech SE
BNTX
$101.81
$3.053.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.98B | 3.30B | 2.91B | 2.95B | 4.12B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.98B | 3.30B | 2.91B | 2.95B | 4.12B |
| Cost of Revenue | 584.76M | 518.02M | 497.44M | 610.40M | 649.19M |
| Gross Profit | 2.39B | 2.78B | 2.41B | 2.34B | 3.47B |
| SG&A Expenses | 648.05M | 660.43M | 662.05M | 614.32M | 603.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 698.51M | 193.20M | -152.88M | -454.03M | -504.32M |
| Total Operating Expenses | 4.37B | 3.78B | 3.35B | 2.89B | 2.68B |
| Operating Income | -1.39B | -475.90M | -441.84M | 60.88M | 1.44B |
| Income Before Tax | -731.97M | -339.05M | -266.01M | 152.62M | 1.27B |
| Income Tax Expenses | -14.84M | 161.73M | 277.75M | 34.17M | 272.68M |
| Earnings from Continuing Operations | -717.13 | -500.78 | -543.77 | 118.45 | 999.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -717.13M | -500.78M | -543.77M | 118.45M | 999.08M |
| EBIT | -1.39B | -475.90M | -441.84M | 60.88M | 1.44B |
| EBITDA | -1.12B | -295.63M | -265.43M | 218.31M | 1.59B |
| EPS Basic | -2.99 | -2.08 | -2.25 | 0.50 | 4.15 |
| Normalized Basic EPS | -1.58 | -0.60 | -0.51 | 0.53 | 3.38 |
| EPS Diluted | -3.00 | -2.11 | -2.28 | 0.48 | 4.10 |
| Normalized Diluted EPS | -1.59 | -0.62 | -0.53 | 0.51 | 3.34 |
| Average Basic Shares Outstanding | 962.81M | 962.27M | 960.39M | 960.99M | 963.06M |
| Average Diluted Shares Outstanding | 965.80M | 966.52M | 965.28M | 965.88M | 970.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |